A powerful new agonist: flooding the system with growth hormone.
Niemczyk et al. treated predialysis chronic kidney disease patients with a new growth hormone-releasing hormone agonist, AKL-0707, and noted important changes in body composition characterized by an increase in fat-free mass, a modest rise in bone mineral content, and a reduction in fat mass. These changes were accompanied by a reduction in both serum urea nitrogen and normalized protein nitrogen appearance rate, while dietary protein intake was unchanged. Importantly, there were no serious adverse events.
Division of Nephrology, Department of Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, USA. Victoria-lim@uiowa.edu
Victoria S
VS
Lim
D001823:Body Composition; D015519:Bone Density; D017322:Clinical Trials, Phase II as Topic; D004311:Double-Blind Method; D013007:Growth Hormone-Releasing Hormone / Q000819:agonists* / Q000378:metabolism; D019382:Human Growth Hormone / Q000009:adverse effects / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism; D008954:Models, Biological; D009765:Obesity / Q000139:chemically induced; D016032:Randomized Controlled Trials as Topic
D019382:Human Growth Hormone; D013007:Growth Hormone-Releasing Hormone